Indiana Governor Mike Pence joined state-based global life sciences and research university executives to unveil the Indiana Biosciences Research Institute, the first industry-led collaborative life sciences research institute in the country. The Indiana Biosciences Research Institute is a statewide public-private partnership advanced by industry group BioCrossroads and led by Indiana’s life sciences industry to discover, develop, and deliver biosciences innovations to improve the lives of Hoosiers and people around the world.
The Indiana Biosciences Research Institute is the result of leadership from industry executives from Eli Lilly and Company, Dow AgroSciences, Roche Diagnostics, Cook Medical, Indiana University Health and Biomet and the Governor of Indiana, with active support in initial development by BioCrossroads. Indiana’s research institutions, including Indiana University, Purdue University and the University of Notre Dame also are participating in the development process.
As part of the Institute development process, industry leaders have defined common scientific interests for research and discovery. The Institute will initially focus on: cardiovascular disease, diabetes, obesity, and nutrition.
The estimated $360-million Indiana Biosciences Research Institute is a non-profit entity expected to be supported largely by corporate and philanthropic funding with oversight from a largely donor-based board of directors representing the life sciences industry, the state of Indiana, academia, and nonprofit donors. The State of Indiana has appropriated $25 million for the biennium for start-up costs. An additional $25 million in start-up funding is being sought from industry and philanthropic sources, which will be used in part to recruit a nationally recognized CEO and research fellows.
